Solid Neoplasms clinical trials at UCSD
1 research study open to eligible people
TAK-676 as Single Agent (SA) and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to determine the safety and tolerability of TAK-676 administered as an SA or in combination with pembrolizumab in participants with advanced or metastatic solid tumors.
La Jolla, California and other locations